We are live on ! Find out more
OSIR

Osiris Therapeutics, Inc. Common Stock
OSIR

Delisted

OSIR was delisted on the 16th of April, 2019.

92 hedge funds and large institutions have $186M invested in Osiris Therapeutics, Inc. Common Stock in 2015 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 26 increasing their positions, 27 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

28% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 18

6% more funds holding

Funds holding: 8792 (+5)

1% more capital invested

Capital invested by funds: $184M → $186M (+$2.6M)

4% less repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 27

89% less call options, than puts

Call options by funds: $385K | Put options by funds: $3.53M

Holders
92
Holders Change
+5
Holders Change %
+5.75%
% of All Funds
2.57%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
23
Increased
26
Reduced
27
Closed
18
Calls
$385K
Puts
$3.53M
Net Calls
-$3.15M
Net Calls Change
+$2.95M
Name Holding Trade Value Shares
Change
Change in
Stake
Citadel Advisors
101
Citadel Advisors
Florida
-$392K -20,330 Closed
PP
102
PDT Partners
New York
-$319K -16,391 Closed
AL
103
AJO LP
Pennsylvania
-$271K -13,910 Closed
ZIM
104
Zacks Investment Management
Illinois
-$260K -13,339 Closed
VOYA Investment Management
105
VOYA Investment Management
Georgia
-$250K -12,822 Closed
Federated Hermes
106
Federated Hermes
Pennsylvania
-$68K -3,472 Closed
BJ
107
BlackRock Japan
Japan
-$23K -1,157 Closed
FMA
108
FNY Managed Accounts
New York
-$19.5K -1,000 Closed
JG
109
Jefferies Group
New York
-$11K -581 Closed
Invesco
110
Invesco
Georgia
-$5K -276 Closed

OSIR Hedge Fund Activity: Q3 2015 in Review

92 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Osiris Therapeutics, Inc. Common Stock (OSIR) for Q3 2015, worth a combined $186M — up 1.4% from $184M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new OSIR positions and 18 closed out — a net gain of 5 holders — while 26 added to existing stakes and 27 trimmed.

The largest buyer was Consonance Capital Management, adding an estimated $16.6M. The largest seller was Venator Capital Management, exiting entirely with an estimated $4.25M sold.

  • 92 institutional investors held Osiris Therapeutics, Inc. Common Stock (OSIR) as of Q3 2015, up from 87 in Q2 2015.
  • Funds reported $186M of Osiris Therapeutics, Inc. Common Stock stock for Q3 2015, up 1.4% quarter-over-quarter.
  • 23 funds opened new Osiris Therapeutics, Inc. Common Stock positions in Q3 2015 and 18 closed out, a net change of +5 holders.
  • The largest Osiris Therapeutics, Inc. Common Stock buyer in Q3 2015 was Consonance Capital Management, an estimated $16.6M added.
  • The largest Osiris Therapeutics, Inc. Common Stock seller in Q3 2015 was Venator Capital Management, an estimated $4.25M sold.

Based on aggregated 13F filings for Q3 2015.